View Older Stories View More Recent Stories

May 25, 2017 08:00AM Merck Enters Exclusive Worldwide License Agreement with Teijin Pharma for Investigational Antibody Candidate Targeting Tau
May 23, 2017 04:36PM Merck (MRK) Granted FDA Approval of KEYTRUDA (pembrolizumab) for Adult & Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer
May 23, 2017 04:34PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer
May 23, 2017 01:19PM Merck Announces Third-Quarter 2017 Dividend
May 23, 2017 06:57AM Merck's (MRK) sBLA for KEYTRUDA to Treat Recurrent or Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Granted FDA Priority Review
May 23, 2017 06:55AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Recurrent or Advanced Gastric or Gastroesophageal Junction Ade
May 22, 2017 11:21AM Merck (MRK) Announces Presentation of Phase 2 Results for MK-7264
May 22, 2017 11:20AM Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
May 19, 2017 08:01AM Merck (MRK) Announces CHMP Opinion Recommending Approval of ISENTRESS 600 mg
May 19, 2017 08:00AM Merck Receives CHMP Positive Opinion Recommending Approval of ISENTRESS® (raltegravir) 600 mg in the European Union
May 19, 2017 04:00AM 100 Healthy Years - Are Kids Prepared?
May 18, 2017 04:01PM Merck (MRK) Says FDA Approves KEYTRUDA for Two New Indications fo Types of Bladder Cancer
May 18, 2017 04:00PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
May 17, 2017 05:21PM Merck (MRK) Says Data for KEYTRUDA Across 16 Types of Cancer to Be Presented at ASCO
May 17, 2017 05:00PM Data for KEYTRUDA® (pembrolizumab) Across 16 Types of Cancer from Merck’s Industry-Leading Immuno-Oncology Program to Be Presented at the 2017 ASCO Annual Meeting
May 17, 2017 05:00PM Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017
May 16, 2017 08:02AM Merck (MRK) to Report New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA® (sitagliptin) & Real-World Evidence Research at ADA Meetings
May 16, 2017 08:00AM Merck to Present New Phase 3 Data on Investigational Ertugliflozin, Additional Analyses of Studies of JANUVIA® (sitagliptin), and Real-World Evidence Research at the 77th Scientific Sessions of the A
May 10, 2017 05:40PM Merck (MRK) Announces FDA Approval for KEYTRUDA as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic NSCLC
May 10, 2017 05:39PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as First-Line Combination Therapy with Pemetrexed and Carboplatin for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespe
May 9, 2017 03:56PM Merck KGaA, Pfizer (PFE) Announce FDA Approval for BAVENCIO for Common Type of Advanced Bladder Cancer
May 9, 2017 03:53PM FDA Grants BAVENCIO® (avelumab) Approval for a Common Type of Advanced Bladder Cancer
May 5, 2017 07:05AM Merck (MRK) Announces EC Approval of KEYTRUDA for Patients with Relapsed/Refractory cHL
May 5, 2017 07:00AM European Commission Approves KEYTRUDA® (pembrolizumab) for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or
May 3, 2017 08:00AM Merck to Present at the Deutsche Bank 42nd Annual Health Care Conference
May 2, 2017 06:45AM Merck Announces First-Quarter 2017 Financial Results
Apr 25, 2017 08:00AM America's Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community
Apr 24, 2017 05:40AM Merck (MRK) Reports New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Apr 22, 2017 07:00AM Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Apr 21, 2017 10:00AM Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chro
Apr 20, 2017 09:00AM Merck Donates $300,000 to Support Neglected Tropical Disease Elimination Efforts in Africa
Apr 19, 2017 08:06AM Merck (MRK) Announces 25 Data Presentations at ECCMID
Apr 19, 2017 08:00AM Merck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017
Apr 18, 2017 08:00AM Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
Apr 18, 2017 08:00AM Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
Apr 10, 2017 04:30PM Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
Apr 7, 2017 07:31AM Merck (MRK) Receives CRL from FDA for TECOS Study with Sitagliptin
Apr 7, 2017 07:30AM Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Apr 6, 2017 10:00AM Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency
Apr 5, 2017 06:53AM Merck (MRK) to Present New Data on ZEPATIER and Investigational Combination Therapy MK-3682B at Liver Congress
Apr 5, 2017 06:50AM Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congre
Apr 3, 2017 07:16AM Ziopharm Oncology (ZIOP), Merck (MRK) & Intrexon (XON) Announce Development Update on CAR-T Therapy for Cancer
Apr 3, 2017 06:45AM Merck to Hold First-Quarter 2017 Sales and Earnings Conference Call on May 2
Mar 31, 2017 07:02AM Incyte (INCY), Merck (MRK) Provide Details on Pact to Investigate Epacadostat and KEYTRUDA
Mar 31, 2017 07:00AM Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)
Mar 24, 2017 08:14AM Merck (MRK) Announces EMA's CHMP Recommends Approval of KEYTRUDA to Treat Classical Hodgkin Lymphoma
Mar 24, 2017 08:13AM European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Mar 23, 2017 05:35PM Pfizer (PFE) and Merck (MRK) BioPharma Unit Get FDA Approval for BAVENCIO® (Avelumab), the 1st Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Mar 23, 2017 05:30PM FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Mar 22, 2017 04:05PM Merck Animal Health Completes Acquisition of Vallée S.A.
View More Recent Stories View Older Stories